Correlation Between Madrigal Pharmaceuticals and Allovir

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Madrigal Pharmaceuticals and Allovir at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Madrigal Pharmaceuticals and Allovir into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Madrigal Pharmaceuticals and Allovir, you can compare the effects of market volatilities on Madrigal Pharmaceuticals and Allovir and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Madrigal Pharmaceuticals with a short position of Allovir. Check out your portfolio center. Please also check ongoing floating volatility patterns of Madrigal Pharmaceuticals and Allovir.

Diversification Opportunities for Madrigal Pharmaceuticals and Allovir

-0.41
  Correlation Coefficient

Very good diversification

The 3 months correlation between Madrigal and Allovir is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Madrigal Pharmaceuticals and Allovir in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allovir and Madrigal Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Madrigal Pharmaceuticals are associated (or correlated) with Allovir. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allovir has no effect on the direction of Madrigal Pharmaceuticals i.e., Madrigal Pharmaceuticals and Allovir go up and down completely randomly.

Pair Corralation between Madrigal Pharmaceuticals and Allovir

Given the investment horizon of 90 days Madrigal Pharmaceuticals is expected to generate 0.66 times more return on investment than Allovir. However, Madrigal Pharmaceuticals is 1.51 times less risky than Allovir. It trades about 0.14 of its potential returns per unit of risk. Allovir is currently generating about -0.04 per unit of risk. If you would invest  23,640  in Madrigal Pharmaceuticals on August 31, 2024 and sell it today you would earn a total of  9,505  from holding Madrigal Pharmaceuticals or generate 40.21% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Madrigal Pharmaceuticals  vs.  Allovir

 Performance 
       Timeline  
Madrigal Pharmaceuticals 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.
Allovir 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allovir has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Madrigal Pharmaceuticals and Allovir Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Madrigal Pharmaceuticals and Allovir

The main advantage of trading using opposite Madrigal Pharmaceuticals and Allovir positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Madrigal Pharmaceuticals position performs unexpectedly, Allovir can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will offset losses from the drop in Allovir's long position.
The idea behind Madrigal Pharmaceuticals and Allovir pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Complementary Tools

Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum